Physician profile
Douglas E Boler
NPI 1558339374
$2,587.29
in general payments reported to CMS, 2019-2025
21 companies · $46.26 in 2025
The $46.26 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,918 · 2020: $448 · 2021: $151 · 2023: $24.27 · 2025: $46.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $430.75 | 2019-2021 | |
| Tersera Therapeutics LLC | $415.16 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.79 | 2019-2020 | |
| Stimwave Technologies Incorporated | $265.96 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $234.53 | 2019-2020 | |
| Boston Scientific Corporation | $213.87 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $197.30 | 2019-2021 | |
| Abbott Laboratories | $153.90 | 2020 | |
| Medtronic USA, INC. | $50.15 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $35.96 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.55 | 2019-2020 | |
| Zyla Life Sciences, INC. | $30.16 | 2019 | |
| Flowonix Medical Incorporated | $30.05 | 2020 | |
| Amgen INC. | $29.53 | 2019 | |
| Almatica Pharma LLC | $28.41 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cgg Medical INC | $24.27 | 2023 | |
| Averitas Pharma INC. | $23.43 | 2025 | Qutenza |
| Biotronik Nro, INC. | $22.83 | 2025 | Prospera |
| Pernix Therapeutics Holdings, INC. | $19.88 | 2019 | |
| Pfizer INC. | $12.39 | 2019 | |
| Zimmer Biomet Holdings, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Boler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.